Results 91 to 100 of about 36,696 (303)

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich   +3 more
wiley   +1 more source

Sensitivity of kochia (Kochia scoparia [L.] Schrader) from three localities to selected sulfonylureas, imazapyr and atrazine

open access: yesPlant Protection Science, 2001
The presence of kochia (Kochia scoparia [L.] Schrader) was discovered at three new localities with different histories of imazapyr use. At the locality Jihlava, kochia was resistant to imazapyr and cross resistant to nine sulfonylureas after long-term ...
Daniela Chodová, Jan Mikulka
doaj   +1 more source

Sulfonylureas

open access: green, 2022
Antonio Pulgar
openalex   +1 more source

Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The combined assessment of multiple abdominal imaging traits in relation to type 2 diabetes remains incompletely characterised. The study examines these relationships on computed tomography (CT) scans from a large‐scale, racially diverse, disease‐focused medical biobank.
Richard H. Tran   +13 more
wiley   +1 more source

Reflections on the Sulphonylurea Story. A Drug Class at Risk of Extinction?:Or A Drug Class Worth Reviving? [PDF]

open access: yes, 2019
The role of sulphonylureas (SUs) in modern clinical practice poses ongoing clinical debate. With the advent of newer agents in diabetes management, there is an increasing shift away from the prescribing of SUs, but not necessarily to more effective ...
Janbon M   +4 more
core   +2 more sources

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye   +8 more
wiley   +1 more source

Resistência cruzada da losna-branca (Parthenium hysterophorus) aos herbicidas inibidores da enzima acetolactato sintase Ragweed parthenium (Parthenium hysterophorus) cross-resistance to acetolactate synthase inhibiting herbicides

open access: yesPlanta Daninha, 2006
A aplicação de um mesmo herbicida, ou de herbicidas com o mesmo mecanismo de ação, durante anos consecutivos, numa mesma área, pode resultar na seleção de biótipos de plantas daninhas resistentes a herbicidas.
D.L.P. Gazziero, A.M. Brighenti, E. Voll
doaj   +1 more source

Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. [PDF]

open access: yes, 2016
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control in patients with type 2 diabetes mellitus (T2DM).
Franch Nadal, Josep   +3 more
core   +2 more sources

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen   +15 more
wiley   +1 more source

Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42) [PDF]

open access: yes, 2017
Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial therapy by diabetes specialists for patients with type 2 diabetes.
Fujihara Kazuya   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy